Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol EIF4B contributors: mct/npt - updated : 28-04-2020
HGNC name eukaryotic translation initiation factor 4B
HGNC id 3285
Location 12q13.13      Physical location : 53.400.061 - 53.435.992
Synonym symbol(s) EIF-4B, PRO1843
DNA
TYPE functioning gene
STRUCTURE 35.76 kb     15 Exon(s)
10 Kb 5' upstream gene genomic sequence study
MAPPING cloned Y linked N status provisional
RNA
TRANSCRIPTS type messenger
identificationnb exonstypebpproduct
ProteinkDaAAspecific expressionYearPubmed
15 - 3871 - 616 - 2018 29483509
15 - 3856 69 611 - 2018 29483509
14 - 3739 - 572 - 2018 29483509
EXPRESSION
Type ubiquitous
   expressed in (based on citations)
organ(s)
SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
Lymphoid/Immunethymus   highly
Reproductivefemale systembreastmammary gland highly
Respiratoryrespiratory tractlarynx  highly
 respiratory tracttrachea  highly
cell lineage
cell lines
fluid/secretion
at STAGE
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • a RNA recognition motif RRM
  • two RNA binding region
  • a region rich in aspartic acid, arginine, tyrosine and glycine (DRYG domain) necessary for the dimerization and binding to eIF3 (Van Gorp 2009)
  • HOMOLOGY
    Homologene
    FAMILY
  • eukaryotic translation initiation factor
  • CATEGORY adaptor
    SUBCELLULAR LOCALIZATION     intracellular
    intracellular,cytoplasm,cytosolic,ribosome
    basic FUNCTION
  • plays a critical role during the initiation of protein synthesis and its activity can be regulated by multiple phosphorylation events (Van Gorp 2009)
  • essential for the binding of mRNA to ribosome stimulating helicase activity of EIF4A1
  • with EIF4H contribute to RNA affinity of the complex through weak interactions not detectable in structural assays (Rozovsky 2008)
  • EIF4G1, EIF4E, EIF4A1, and EIF4B, facilitate the recruitment of mRNA onto the preassembled 43S pre-initiation complex (PIC), thus leading to the formation of the 48S PIC
  • CELLULAR PROCESS cell life, proliferation/growth
    PHYSIOLOGICAL PROCESS
    text control of cell growth
    PATHWAY
    metabolism
    signaling
  • MELK-EIF4B signaling axis that regulates protein synthesis during mitosis, and consequently influences cancer cell survival
  • a component
  • component of the elongation initiation factor 4 (EIF4F)
  • part of eIF4A/4G/4H helicase complex (Marintchev 2008)
  • INTERACTION
    DNA
    RNA binding
    small molecule
    protein
  • EIF3
  • EIF4H is much less efficient at stimulating EIF4A1 unwinding activity than EIF4B, implying that EIF4H is not able to completely substitute for EIF4B in duplex unwinding
  • EIF4B is a critical substrate of PIM kinases in mediating the activity of ABL oncogenes
  • PIM2 promotes liver tumorigenesis induction through mediating survival and preventing apoptosis of liver cell
  • molecularly, RPS6KB1 enhances MYC translation efficiency by modulating the phosphorylation of eukaryotic initiation factor EIF4B, which is critical to unwind its structured 5' untranslated region (5'UTR)
  • EIF4B is a MELK-interacting protein during mitosis and a bona fide substrate of MELK
  • CHRM3 modulate EIF4B phosphorylation via the ERK1/2 and PKC signaling pathways in colon cancer cells
  • EIF4B is a bonafide substrate of USP11, which stabilizes and enhances EIF4B activity
  • GMAN directly combined with EIF4B and promoted its phosphorylation at serine-422 by preventing EIF4B binding and dephosphorization of the protein phosphatase 2A subunit B 6)
  • cell & other
    REGULATION
    Other regulated by phosphorylation (a novel mechanism by which PTK2B can regulate protein translation and may be critical for the transforming potential of this AGC kinase family member) (Van Gorp 2009)
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
  • EIF4B, DAXX and ERCC5 are identified as novel prognostic markers for poor survival in diffuse large B-cell lymphoma (DLBCL)
  • Therapy target
    SystemTypeDisorderPubmed
    cancerhemopathy 
    is a candidate therapeutic target for treatment of ABL-induced cancers (PMID: 23749639)
    ANIMAL & CELL MODELS